MedTrace Logo

Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

NCT06532890 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2026-03-25

No results posted yet for this study

Summary

This study aims to discover circulating microRNAs (associated with drug doses and levels) that can be used to characterize the overall immune state in pediatric heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.

Conditions

  • Cardiac Failure
  • Graft Rejection

Sponsors & Collaborators

  • Inova Health Care Services

    lead OTHER

Principal Investigators

  • Palak Shah, MD · Inova Schar Heart and Vascular

  • Jason Goldberg, MD · Inova L.J. Murphy Children's Hospital

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-06
Primary Completion
2029-10-01
Completion
2029-10-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06532890 on ClinicalTrials.gov